Evolus, Inc. (NASDAQ:EOLS) Given Consensus Rating of “Moderate Buy” by Analysts

by · The Cerbat Gem

Evolus, Inc. (NASDAQ:EOLS – Get Free Report) has been given an average recommendation of “Moderate Buy” by the six brokerages that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $16.00.

Several equities research analysts recently commented on EOLS shares. Weiss Ratings upgraded Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. BTIG Research reiterated a “buy” rating and issued a $13.00 price target on shares of Evolus in a report on Wednesday, March 4th. Mizuho set a $15.00 price objective on Evolus in a research note on Wednesday, February 4th. HC Wainwright lowered their price objective on Evolus from $20.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. Finally, Wall Street Zen downgraded Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th.

Check Out Our Latest Report on Evolus

Insider Buying and Selling at Evolus

In other news, insider David Moatazedi sold 116,720 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total value of $570,760.80. Following the completion of the transaction, the insider directly owned 618,369 shares of the company’s stock, valued at $3,023,824.41. This trade represents a 15.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rui Avelar sold 29,996 shares of the firm’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total value of $146,680.44. Following the completion of the transaction, the insider directly owned 430,542 shares of the company’s stock, valued at $2,105,350.38. The trade was a 6.51% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 163,504 shares of company stock valued at $797,184. 5.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Evolus

Hedge funds have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue bought a new stake in Evolus during the third quarter worth about $26,000. Larson Financial Group LLC lifted its stake in shares of Evolus by 136.6% in the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after acquiring an additional 2,837 shares during the last quarter. Meeder Asset Management Inc. bought a new stake in shares of Evolus in the 4th quarter valued at about $34,000. Wexford Capital LP bought a new stake in shares of Evolus in the 3rd quarter valued at about $37,000. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Evolus by 340.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock valued at $68,000 after acquiring an additional 5,691 shares during the last quarter. Institutional investors own 90.69% of the company’s stock.

Evolus Stock Performance

Shares of EOLS opened at $6.50 on Friday. Evolus has a 52 week low of $3.86 and a 52 week high of $10.62. The stock has a market capitalization of $428.09 million, a price-to-earnings ratio of -9.70 and a beta of 1.28. The stock has a fifty day moving average of $5.04 and a 200-day moving average of $5.62.

Evolus (NASDAQ:EOLS – Get Free Report) last issued its earnings results on Monday, May 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The business had revenue of $73.14 million during the quarter, compared to analyst estimates of $72.52 million. During the same period in the previous year, the firm posted ($0.30) earnings per share. As a group, equities analysts forecast that Evolus will post -0.41 EPS for the current year.

Evolus Company Profile

(Get Free Report)

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.

Read More